RYBREVANT
PreclinicalBiologic
Johnson & JohnsonRYBREVANT is one of 15 biologic programs targeting Lung Carcinoma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
14
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[2]
Indication
Competition
Competitive Landscape
14 competitors in Lung Carcinoma
#DrugCompanyPhaseTrials
1Lumakras
AmgenApproved
Afinitor
NovartisApproved
Iressa
AstraZenecaApproved
Aurlumyn
BBTG International Inc.
Approved
Chantix
PPrism Pharmaceuticals
Approved
Navelbine
PPierre Fabre Medicament
Approved
Leukine
SanofiPhase 2
Nicorette
PfizerPreclinical
Montanide ISA 51 VG
NNational Cancer Institute (NCI)
Phase 2
Nicotine Replacement
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Regulatory
FDA Approval Timeline[3]
May 21, 2021
RYBREVANT
BLA BLA761210
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for RYBREVANT. EMBL-EBI & Wellcome Sanger Institute.
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[1]
- Highest Phase
- Preclinical
- Company